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130 The Journal of Thoracic and Cardackground: Pulmonary artery banding is proposed as a first palliation in infants
ith complex congenital heart disease and high pulmonary blood flow. In addition,
t may be used to retrain the left ventricle. Optimal tightening may be difficult to
btain, leading to reoperation. An implantable device for pulmonary artery banding
ith telemetric control was recently developed allowing for repeated adjustments,
ut it is presently limited to patients weighing less than 20 kg. In large animals, we
ested an off-label adjustable gastric banding system for pulmonary artery banding.
ethods and Results: Fourteen ewes weighing 50 to 75 kg underwent implantation
f the Lap-Band device (BioEnterics Corp, Santa Barbara, Calif) around the main
ulmonary artery through a left thoracotomy. All had functional evaluation with
rogressive occlusion and opening of the device at implantation and every 2 weeks
ntil sacrifice immediately after implantation (group 1, n  8), at 1 month (group
, n  3), at 3 months (group 3, n  3), or death. Invasive pressure measurements
n the right ventricle and aorta were carried out each time. Devices were easily
mplanted in all animals. Progressive occlusion and reopening were possible in all
nimals during each time point. Two animals died of right heart failure related to
xcessive tightening of the band. Retrieval of the device without any major damage
as possible in 12 of 14 animals.
onclusion: With this implantable device, we were able to adjust the pulmonary
rtery diameter in animals. Patients requiring left ventricle retraining and weighing
ore than 30 kg would benefit from the device’s use in humans.
n patients with corrected transposition of the great arteries, the double-switch
operation is a surgical option, but left ventricle pumping in the pulmonary
circulation needs to be retrained to assume the systemic work load.1-3 Pulmo-
ary artery banding (PAB) has been used to increase left ventricular afterload in
uch situations.4,5 Tightening of the band is problematic, and some patients require
PAB reoperation because of excessive tightening, leading to left ventricular
ysfunction, or insufficient tightening with inappropriate ventricular preparation.
hese reoperations are associated with increased morbidity and mortality. In these
atients, a dilatable banding system is of interest. To date, only 1 adjustable device
ie, the FlowWatch, EndoArt S.A., Lausanne, Switzerland) is presently available,
ut its use is limited to small children weighing less than 20 kg.6-9 The Lap-Band
djustable banding system (BioEnterics Corp, Santa Barbara, Calif) was initially
esigned to induce a restriction to the gastric diameter in severely obese pa-
ients.10-12 We investigated the off-label use of this device to create an adjustable
AB. We report here the preliminary experimental application.
ethods and Materials
evice Description
he Lap-Band adjustable banding system is a 13-mm–wide band that, when fastened, forms
 circular ring with an inside circumference of 9.75 cm (Figure 1). The band is made of
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Diocompatible silicon elastomers. The inner surface of the band is
nflatable and connected by 50-cm kink-resistant tubing to an
ccess port placed subcutaneously. The tubing might be shortened
o tailor the position of the port to the size of animals. A locking
echanism is located around the ring to avoid undesired opening
f the band during inflation. The device is available in different
izes. For this application, we used the smallest commercially
vailable device with a circumference of 9.75 cm. When the device
s clipped, the dimensions are 13 mm (width), 26 mm (internal
iameter), and 38 mm (external diameter). The adjustable area in
fully open position corresponds to a pulmonary artery (PA)
iameter of 26 mm and is fully closed after injection of 10 mL of
aline, theoretically allowing for PAB in adolescents and adults
Figure 2). No energy is required to reduce the diameter of the
evice. The change in the adjustable area is obtained by saline
njection in the inner surface of the band from the access port along
he tubing.
nimal Preparation
ourteen ewes weighing 55 to 75 kg were included in the present
tudy and divided into 3 groups according to the time of sacrifice.
ight animals were sacrificed acutely (group 1), whereas the
emaining 6 were kept alive for 1 month (group 2) and 3 months
group 3). Acute group was performed to evaluate (1) the appli-
ability of the off-label use of the device around the PA and (2) the
ossibility of progressively narrowing and releasing the PA with
alloon inflation and deflation. In groups 2 and 3, we tested the
unction of the device up to 12 weeks after its implantation, with
epeated adjustments of PAB. All animals received medical care
ccording to the European Guidelines for Laboratory Animal
are.13
nsertion of the Adjustable Pulmonary Artery Banding
wes were sedated with an intravenous injection of pentothal
10 mg/kg body weight), placed in a lateral position, intubated,
nd ventilated with 100% oxygen and 1% halothane. Anesthesia
Abbreviations and Acronyms
PA  pulmonary artery
PAB pulmonary artery bandingThe Journal of Thoracicas maintained with halothane (0.5%-3%). Cardiac and respira-
ory functions were monitored throughout the procedure. A left
horacotomy was performed in the fourth intercostal space. The
ericardium was longitudinally opened. The main PA was dis-
ected posteriorly. To avoid the risk of secondary migration, the
issection was limited to the space needed to insert the system
1.5 cm). A device was opened, straightened, and placed around
he main PA. Particular attention was taken not to traumatize the
essel and surrounding structures when passing the system around
he main PA. The locking mechanism of the device was left
nteriorly after closure of the device to test the possibility of
etrieval. The device was not sutured to the main PA. After the
valuation (see below), animals were sacrificed (acute study, group
) or extubated (chronic study, groups 2 and 3). Drains were
emoved 2 to 3 hours after the animals were completely awake.
ostoperative medical treatment consisted of antibiotics for 48
ours and analgesia.
emodynamic Assessment
fter the device was inserted, all ewes underwent hemodynamic
valuation consisting of invasive measurements of right ventricu-
ar, PA, and aortic pressures. Pressures were measured after se-
uential inflations of saline in the access port connected to the
and. Pressure catheters were inserted into the right ventricle after
ts direct puncture and into the distal PA for simultaneous pressure
onitoring. An arterial femoral access was obtained to assess
ystemic blood pressure. For long-term study, the ventricular cath-
ter was fixed to the right ventricle with a 3-0 nonresorbable
hread. The extremity of the catheter was connected to an access
ort placed and fixed subcutaneously near the device port. The
atheter was flushed with heparin to limit the risk of occlusion. At
he time of control, femoral artery access was gained for systemic
lood pressure control, and 2 access ports (RV catheter and device)
ere punctured with two 22-gauge needles. Pressures were re-
orded simultaneously. Maximal inflation volume leading to
brupt systemic pressure drop and its corresponding right ventric-
lar pressure were first determined. Various inflations were then
ade with a decrement of 0.2 mL from the maximal inflation
olume until normalization of the right ventricular pressure. The
inimal inflation volume was determined and defined as the
olume of saline leading to normalization of right ventricular
ressure. Smaller decrements and increments of 0.1 mL were nec-
ssary to determine precisely the minimal inflation volume. Measure-
Figure 1. Band in closed (A) and opened (B)
positions. ap, Access port; ip, inflatable part; lm,
locking mechanism; t, kink-resistant tubing.and Cardiovascular Surgery ● Volume 131, Number 5 1131
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Dents were made after 2 minutes to obtain a steady state. A period of
minutes was respected between inflations to achieve complete
ecovery of systemic pressure and return to baseline conditions.
ollow-up of Animals in Groups 2 and 3
or long-term observation, ewes were transferred to a farm. Ani-
als were reassessed weekly in group 2 (weeks 1, 2, 3, and 4) and
very 2 weeks in group 3 (weeks 2, 4, 6, 8, 10, and 12). The
ssessment was performed sooner if any symptoms occurred.
eevaluation consisted of a hemodynamic assessment under gen-
ral anesthesia. We expected to leave the band inflated at the end
f each reassessment with a saline volume of minimum inflation
olume plus 0.3 mL. This inflation volume was recorded and
ompared with the saline volume to full deflation at the beginning
f each control to assess the porosity of the device.
raft Retrieval
ll grafts were explanted at the end of the protocol (ie, acutely in
roup 1, after 1 month in group 2, and after 3 months in group 3).
n group 1, devices were retrieved with a beating heart to assess the
asiness of retrieval. Elsewhere, the heart and lungs were retrieved
ogether in 1 block. All hearts were dissected and inspected macro-
copically. The pulmonary vascular tree was examined to determine
he position of each device in relation to adjacent structures. The
ossibility of device retrieval was studied in groups 2 and 3.
esults
nimals in Group 1
he acute experimental study confirmed the easy insertion
f the device around the main PA (8/8) without any damage a
132 The Journal of Thoracic and Cardiovascular Surgery ● Mao the surrounding structures (Figure 3). The invasive pres-
ure assessment showed the appearance of a pressure gra-
ient between the proximal and distal part of the adjustable
and. This gradient increased progressively in parallel with
Figure 2. Band in different degrees of infla-
tion. A, Steady state. B, After inflation of 2 mL
of saline. C, Configuration after inflation of 5
mL of saline. D, Complete closure of the band
(10 mL).
igure 3. Surgical views showing the band after its placement
round the main pulmonary artery.
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Dhe occlusion of the device and instillation of saline. The
eopening of the device was followed by progressive reduc-
ion of the pressure gradient and right ventricular pressure.
he mean maximum right ventricular pressure was 85 mm
g (range 65-95 mm Hg), and the inflation volume was 6
L (range 5.8-6.3 mL). Hemodynamic data are shown in
able 1. It was possible to retrieve the band in all animals
efore sacrifice.
nimals in Groups 2 and 3
n the acute study, all devices were implanted without
ny problem. Acute measurements were not different
rom group 1. The postoperative course was uneventful in
ll animals.
Reassessment was performed weekly in all group 2 an-
mals. In group 3, only 1 animal was reassessed as planned.
n the remaining 2 animals, assessments were performed as
lanned until week 6 after the initial procedure. Because of
rganizational problems, testing was delayed and performed
week (week 9) after the planned control (week 8).
No animals in group 2 died during the entire follow-up,
hereas 2 animals in group 3 died. One animal died afterl
nesthetic induction (week 9). At autopsy, signs of right
entricular failure (ie, pleural effusion and right ventricular
nlargement) were found. The second animal, also tested at
eek 9, had a pericardial effusion (1.5 L) that was drained.
ressure measurements indicated right ventricular failure.
herefore, the band was left open after the procedure to
llow for recovery of the right ventricle. The animal was
ound dead in its cage at week 10. The same features were
ound at autopsy. After this problem, the PAB was left open
fter each testing in the remaining animal in group 3; the
nimal had an uneventful follow-up until sacrifice at 12
ABLE 1. Data from animals in group 1 (acute study)
Animal
umber
MaxInfVol/
MaxRVP
(mL/mm Hg)
MinInfVol 
0.3 mL/RVP
(mL/mm Hg)
MinInfVol/
MinRVP
(mL/mm Hg)
1 6.3/90 5.3/30 5.0/20
2 5.9/65 5.1/35 4.8/15
3 6.0/88 5.3/25 5.0/18
4 6.1/92 5.5/33 5.2/22
5 5.8/86 5.2/26 4.9/14
6 5.8/75 5.3/30 5.0/20
7 6.2/95 5.3/24 5.0/16
8 5.9/89 5.2/35 4.9/25
ean 6/85 5.3/30 5.0/19
ange 5.8-6.3/65-95 5.1-5.5/24-35 4.8-5.2/14-25
he minimal inflation volume was determined and defined as the volume of
aline leading to normalization of RVP. The maximal inflation volume was
he volume leading to abrupt systemic pressure drop. MaxInfVol, Maximal
nflation volume; MaxRVP, maximal right ventricular pressure; MinInfVol,
inimal inflation volume; MinRVP, minimal right ventricular pressure.eeks after device insertion. w
The Journal of ThoracicAt the 1-week evaluation in group 2, a small skin inci-
ion was necessary in 2 animals to locate the port because
ntry through the access port connected to the RV pressure
as not possible. It was refixed subcutaneously at the end of
he study, and its access was possible at each following
tudy. One animal had a subcutaneous infective collection
hat was treated by surgical evacuation and resection of
nfective tissue. Because the ports were left in place, a
omplete cure was not possible and the animal continued to
xperience local suppuration throughout the protocol.
Full deflation of the balloon was always possible at the
eginning of the reassessment. Perfect equivalence was
ound when comparing the saline volume with full deflation
n the beginning of each control and the inflation volume
eft at previous controls, reflecting the absence of fluid loss
hrough the system.
In all animals, repeated inflation and deflation of the
evice were confirmed at implantation and during each
esting throughout the protocol. Hemodynamic data at each
ontrol are shown in Figures 4 and 5. There was a good
orrelation between volume inflation and ventricular pres-
ure increase; maximum and minimum volume inflation and
ressure regimen response values were in the same range.
ith time, response to the same volume inflation was vari-
ble when compared individually.
Animals in group 2 were sacrificed as planned after a
ean time from implantation of 4.5 weeks (range 4-5
eeks). In animals in groups 2 and 3, the device was still
unctioning. The device was easily identified through a
horacic incision; it was located in the same position of
mplantation, without any migration of the device. Before
etrieval, macroscopic examination revealed that 4 of 6
evices were free of any process (3 from group 2 and 1 from
roup 3). Removal of the device was possible in those
nimals without any lesion to the surrounding structures,
leeding, or hemodynamic disturbance (Figure 6). The PA
as not altered macroscopically. Elsewhere, fibrous tissue
Figure 4. Data from group 2.as present, completely surrounding the device (2 animals
and Cardiovascular Surgery ● Volume 131, Number 5 1133
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Dn group 3) and making its retrieval difficult without any
esion to the PA.
iscussion
everal attempts at developing an adjustable PAB have
een made, but only 1 device is commercially available.
he FloWatch system is capable of repeated narrowing and
eleasing of the PA with a telemetric control. This device is
resently used in humans, but its use is limited to small
hildren weighing less than 20 kg. Older patients might
eed an adjustable PAB. We investigated the use of an
ff-label adjustable device for gastric restriction. Our ex-
erimental study demonstrated that the device is easy to
mplant and use. Repeated narrowing and releasing of the
igure 5. Data from group 3. **Not performed. *Time of death.
nimal 1 died after anesthetic induction before device and pres-
ure control at week 9. Animal 2 was found dead at week 10 in
he farm.134 The Journal of Thoracic and Cardiovascular Surgery ● MaA were possible in the acute and chronic study groups.
urthermore, no loss of fluid was found when comparing
olume with full deflation at the beginning of testing and
olume left at the end of the previous testing, reflecting the
bsence of porosity of the device. At the time of explanta-
ion, retrieval of the device was always possible in animals
ith the shortest follow-up. However, it is probable that the
evice will be covered by fibrous tissue making its retrieval
ore difficult after a long period of time, as seen in 2
nimals in which the implant was left for 10 and 12 weeks.
his could hamper or complicate further surgery, making
lastic repair of the PA mandatory before the double-switch
peration can be performed in humans. In such a popula-
ion, the use of the device should probably be limited in time
ith rapid training. Death occurred in 2 animals from group
, due to right ventricular failure. Indeed, scheduled testing
rocedures and release of the device had to be delayed for
week because of organizational problems. When the 2
nimals were tested, right ventricular failure was demon-
trated; 1 animal died at anesthetic induction, and 1 animal
ied after 1 week despite complete release of the banding.
loser follow-up would clearly have avoided this fatal
ssue. One of the difficulties we encountered was the need
or anesthesia to test the device. It is probable that the level
f narrowing was too high, leading to heart failure in awake
nimals. This was not seen in animals tested weekly but in
nimals tested every 2 to 3 weeks. It would have been more
ppropriate to test the device in fully awake animals, at rest
r even at exercise, to properly assess the capability of the
ight ventricle to cope with the increased afterload. In hu-
ans, the assessment would be easier and allow narrowing
r releasing of the banding system under echocardiographic
Figure 6. Anatomic pictures showing the de-
vice during its retrieval after 1 month of in-
sertion. A, Band still around the pulmonary
artery with the locking mechanism clipped. B,
The locking mechanism has been opened. C,
Partial retrieval of the band. D, Complete re-
trieval of the band. Note that complete re-
trieval is possible without extensive dissec-
tion.y 2006
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Dontrol in nonsedated patients. Exercise could, moreover, be
imulated using intravenous drugs.
Patients with a morphologic right ventricle in the sys-
emic circulation (as seen in corrected transposition of the
reat arteries or previous atrial switch operation) may re-
uire a PAB for retraining of the left ventricle before
natomic biventricular repair. Whether a left ventricle can
r cannot be retrainable after a certain age is still contro-
ersial. In most studies, there is a “clear” cutoff.1,2 Patients
n whom left ventricular retraining is started before the age
f 12 years have a greater rate of completion than older
atients with the current banding protocol. The problem
ith this management, particularly in asymptomatic pa-
ients, is the risk of failure (ie, debanding, left ventricular
ailure, transplantation, and death). We are convinced that
he type of retraining is crucial, as recently demonstrated by
e Bret and colleagues14 in an experimental study. It is
ossible that, as advocated by them, fitness defined as
epeated periods of training followed by complete relapse of
he afterload is preferable to a constant training that may
ead to ventricular fibrosis. However, the so-called fitness
echnique is difficult to perform in clinical practice with
onventional PA banding but would clearly be possible with
he Lap-Band device. The results of left ventricle retraining
ith the new device may be better in an older population, in
hom there is an inconsistent response to left ventricular
etraining. The best way to retrain a left ventricle is still
nknown. In particular, periodicity, timing, and length of
raining are to be defined. Another benefit of the Lap-Band
evice is the ability to restore the initial pressure regimen
hen needed. It has a dual implication. First, the postoper-
tive course could be facilitated by the complete release of
he banding with retraining started after a few days with the
atient in physiologic hemodynamic conditions. Second, in
ase the device is not tolerated, it could be completely
eleased and left open without requiring any reintervention
or PA debanding.
onclusion
e described the off-label use of a device capable of
epeated narrowing and releasing of the PA with external
ontrol in adult animals. The preliminary experimental
tudy demonstrated the feasibility of the implant and good
unction of the device up to 12 weeks after its insertion. Of
ourse, long-term experimental studies will be required
efore human application, but preliminary results are promis-
The Journal of Thoracicng. The use of this device in humans would have tremendous
enefit on the management of congenital heart diseases. The
ize of the currently available device will limit the clinical
pplication to patients weighing more than 40 kg, and there-
ore a smaller size will be necessary for smaller children.
The authors thank BioEnterics Corporation for providing the
ystem and the URC of Necker Hospital for technical support.
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